Assal RE, Guven S, Gurkan UA, et al. Bio-inspired Cryo-ink Preserves Red Blood Cell Phenotype and Function during Nanoliter Vitrification. 2014, Advanced materials, 26(33):5815-5822.
Akron Biotech is an expert in cGMP products (Recombinant proteins, human Fibronectin, and human plasma-derived products).
Akron Biotech offers a wide variety of cell culture tools such as recombinant proteins, human plasma-derived products (such as AB-serum, HAS and insulin), cryo-media and custom media and media supplements which are available in research and GMP quality.
At Akron you can also find high-quality and cGMP-compliant plasmid DNA for pre-clinical all the way to commercial gene therapy.
Facts about Akron. References.
Burke CJ, Zylberberg C. Sources of Variability in Manufacturing of Cell Therapies. Regenerative Engineering and Translational Medicine, 2019, DOI 10.1007/s40883-019-00130-5
Harrison RP, Zylberberg E, Ellison S, Levine BL. Chimeric antigen receptor–T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods. Cytotherapy, 2019, In Press.
El Assal, L. Abou‐Elkacem, A. Tocchio, S. Pasley, S. Matosevic, D. L. Kaplan, C. Zylberberg, U. Demirci. Bioinspired Preservation of Natural Killer Cells for Cancer Immunotherapy. Adv. Sci.2019, 1802045.
Bruce CJ, Guojun B, Centanni JM, Davis MD, Dobson J, Hare JM, Fields GB, Jove R, Kenyon N, Kahn A, March K, Matosevic S, Mahmood A, Pepine CJ, Ricordi C, Shapiro SA, Zylberberg C, Zylberberg E. Regenerative Medicine in the State of Florida: Letter Outlining the Florida Organization for Regenerative Medicine. Stem Cells Translational Medicine, 2018, 7(7): 511-512.
National Academies of Sciences, Engineering, and Medicine. 2017. Navigating the Manufacturing Process and Ensuring the Quality of Regenerative Medicine Therapies: Proceedings of a Workshop. Washington, DC: The National Academies Press.
Zylberberg C and Matosevic S. Bioengineered liposome-scaffold composites as therapeutic delivery systems. Therapeutic Delivery, 2017, 8(6):425-445.
Zylberberg C, Gaskill K, Pasley S, Matosevic S. Engineering liposomal nanoparticles for targeted gene therapy. Gene Therapy, 2017, 24(8):441-452.
Haddock R, Lin-Gibson S, Lumelsky N, McFarland R, Roy K, Saha K, Zhang J, Zylberberg C. Manufacturing Cell Therapies: The Paradigm Shift in Health Care of This Century. 2017, National Academy of Medicine, 1-13.
Buckler L, Kunkel E, Thompson M, Ehrhardt R. Technological developments for small-scale downstream processing of cell therapies. 2016, Cytotherapy, 18(3):301-306.
MForesight: Alliance for Manufacturing Foresight. Biomanufacturing Technologies for Regenerative Medicine. 2016.
Zylberberg C, Matosevic S. Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape. 2016, Drug delivery, 23(9):3319-3329.
Solomon J, Csontos L, Clarke D, Bonvhadi M, Zylberberg C, McNiece I, Kurtzberg J, Bell R, Deans R. Current perspectives on the use of ancillary materials for the manufacture of cellular therapies. 2016, Cytotherapy, 18(1):1-12.
Knapinska A, Amar S, He Z, Matosevic S, Zylberberg C, Fields G. Matrix metalloproteinases as reagents for cell isolation. Enzyme and Microbial Technology, 2016, 93-94:29-43.
Porat Y, Abraham E, O Karnieli, Nahum S, Woda J, Zylberberg C. Critical elements in the development of cell therapy potency assays for ischemic conditions. 2015, Cytotherapy, 17(7):817-831.
Abbott S, MacKay G, Durdy M, Solomon S, Zylberberg C. Twenty years of the International Society for Cellular Therapies: the past, present and future of cellular therapy clinical development. 2014, Cytotherapy, 16(4):S112-S119.
